NBIX Stock: Neurocrine Biosciences, Inc. Stock Price, Analysis & Insights
Get live NBIX stock price $160.86, comprehensive Neurocrine Biosciences, Inc. stock analysis, charts, news, and expert forecast. Real-time NBIX stock data and investment insights.
Loading chart data...
Investment Score
A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and market...
Company Information
- CEO
- Kyle W. Gano
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1800
Contact Information
- Website
- https://www.neurocrine.com
- Address
- 12780 El Camino Real
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 24.8)
✓ Lower volatility stock (Beta: 0.40) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Neurocrine Biosciences, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Neurocrine Biosciences, Inc.
- ⚠Investors should consider how Neurocrine Biosciences, Inc. fits within their overall portfolio allocation
Market Cap
16.17B
P/E Ratio (TTM)
24.79
Beta
0.40
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare NBIX with peer companies:
- Price
- $67.69
- Market cap
- 13.20B
- Price
- $22.87
- Market cap
- 11.42B
- Price
- $76.01
- Market cap
- 16.97B
- Price
- $144.59
- Market cap
- 11.07B
- Price
- $13.30
- Market cap
- 11.07B
- Price
- $13.05
- Market cap
- 10.12B
- Price
- $30.90
- Market cap
- 13.11B
- Price
- $49.48
- Market cap
- 8.64B
- Price
- $144.82
- Market cap
- 9.07B
- Price
- $15.77
- Market cap
- 18.36B
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.